Inozyme Pharma (NASDAQ:INZY) Receives “Outperform” Rating from Wedbush

Wedbush restated their outperform rating on shares of Inozyme Pharma (NASDAQ:INZY) in a research note published on Tuesday, RTT News reports. They currently have a $15.00 price target on the stock.

Several other brokerages have also weighed in on INZY. HC Wainwright reissued a buy rating and issued a $14.00 price objective on shares of Inozyme Pharma in a report on Tuesday. Wells Fargo & Company assumed coverage on Inozyme Pharma in a report on Thursday, May 30th. They issued an overweight rating and a $14.00 price target for the company. Bank of America reduced their price objective on Inozyme Pharma from $16.00 to $14.00 and set a buy rating on the stock in a research note on Tuesday, April 9th. Finally, Needham & Company LLC reiterated a buy rating and set a $23.00 target price on shares of Inozyme Pharma in a research note on Wednesday, May 8th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Inozyme Pharma currently has a consensus rating of Buy and a consensus target price of $16.00.

Inozyme Pharma Stock Up 0.2 %

INZY stock opened at $4.42 on Tuesday. The company has a current ratio of 14.05, a quick ratio of 14.05 and a debt-to-equity ratio of 0.38. The firm has a 50 day simple moving average of $4.60 and a 200-day simple moving average of $5.09. The company has a market capitalization of $273.42 million, a P/E ratio of -3.23 and a beta of 1.53. Inozyme Pharma has a twelve month low of $2.69 and a twelve month high of $7.80.

Inozyme Pharma (NASDAQ:INZY) last announced its quarterly earnings data on Tuesday, May 7th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.03). On average, equities research analysts predict that Inozyme Pharma will post -1.59 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in INZY. Kennedy Capital Management LLC increased its stake in shares of Inozyme Pharma by 52.2% in the first quarter. Kennedy Capital Management LLC now owns 437,657 shares of the company’s stock valued at $3,352,000 after purchasing an additional 150,120 shares during the period. Affinity Asset Advisors LLC grew its holdings in Inozyme Pharma by 40.1% in the 1st quarter. Affinity Asset Advisors LLC now owns 2,642,519 shares of the company’s stock worth $20,242,000 after buying an additional 756,717 shares in the last quarter. Vanguard Group Inc. increased its position in Inozyme Pharma by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 2,419,020 shares of the company’s stock valued at $18,530,000 after acquiring an additional 33,998 shares during the period. Eventide Asset Management LLC raised its stake in Inozyme Pharma by 1.8% during the 4th quarter. Eventide Asset Management LLC now owns 3,179,837 shares of the company’s stock valued at $13,546,000 after acquiring an additional 54,837 shares in the last quarter. Finally, Superstring Capital Management LP acquired a new position in Inozyme Pharma during the 4th quarter worth $528,000. 88.30% of the stock is currently owned by institutional investors.

About Inozyme Pharma

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.